ES2190396T3 - Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. - Google Patents

Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Info

Publication number
ES2190396T3
ES2190396T3 ES00401039T ES00401039T ES2190396T3 ES 2190396 T3 ES2190396 T3 ES 2190396T3 ES 00401039 T ES00401039 T ES 00401039T ES 00401039 T ES00401039 T ES 00401039T ES 2190396 T3 ES2190396 T3 ES 2190396T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
compositions containing
preparation procedure
new amino
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00401039T
Other languages
English (en)
Inventor
Jean-Luc Fauchere
Jean-Claude Ortuno
Jacques Duhault
Jean Albert Boutin
Nigel Levens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Application granted granted Critical
Publication of ES2190396T3 publication Critical patent/ES2190396T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de fórmula (I) según la reivindicación 1, para los cuales Z representa un grupo seleccionado entre alquilo, arilo eventualmente sustituido, y heteroarilo eventualmente sustituido, sus enantiómeros distereoisómeros así como sus sales de adición de un ácido o de una base farmacéuticamente aceptable.
ES00401039T 1999-04-15 2000-04-14 Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. Expired - Lifetime ES2190396T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9904721A FR2792314B1 (fr) 1999-04-15 1999-04-15 Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
ES2190396T3 true ES2190396T3 (es) 2003-08-01

Family

ID=9544433

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00401039T Expired - Lifetime ES2190396T3 (es) 1999-04-15 2000-04-14 Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Country Status (19)

Country Link
US (2) US6245916B1 (es)
EP (1) EP1044970B1 (es)
JP (1) JP2000309579A (es)
KR (1) KR20010020732A (es)
CN (1) CN1145616C (es)
AT (1) ATE231133T1 (es)
BR (1) BR0001602A (es)
CA (1) CA2305940A1 (es)
DE (1) DE60001190T2 (es)
DK (1) DK1044970T3 (es)
EA (1) EA003023B1 (es)
ES (1) ES2190396T3 (es)
FR (1) FR2792314B1 (es)
HU (1) HUP0001562A3 (es)
NO (1) NO20001964L (es)
NZ (1) NZ504023A (es)
PL (1) PL339690A1 (es)
SI (1) SI1044970T1 (es)
ZA (1) ZA200001908B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
WO2002078697A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
MXPA02010231A (es) 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7652051B2 (en) * 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
MX2007003327A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP1799667B1 (en) * 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US20080167321A1 (en) * 2004-09-20 2008-07-10 Xenon Pharmaceuticals Inc. Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
US7547698B2 (en) * 2004-09-20 2009-06-16 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)
EP2269610A3 (en) * 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003332A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
ES2325773T5 (es) * 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
BRPI0611187A2 (pt) * 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
MX2008009215A (es) * 2006-01-17 2008-12-10 Barrier Therapeutics Inc Tratamiento de trastornos inflamatorios con compuestos de triazol.
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008047544A1 (en) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
JP2011500625A (ja) 2007-10-18 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリ置換された１，２，４−トリアゾール
KR20100098628A (ko) * 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
MY152486A (en) * 2008-03-19 2014-10-15 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 - triazoles as nicotinic acetylcholine receptor modulators
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
WO2009135944A1 (en) * 2008-05-09 2009-11-12 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US8775245B2 (en) 2010-02-11 2014-07-08 News America Marketing Properties, Llc Secure coupon distribution
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
ME02169B (me) * 2010-10-01 2015-10-20 Taisho Pharmaceutical Co Ltd Derivat 1,2,4-triazolona
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AU2017342083A1 (en) 2016-10-14 2019-04-11 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
PT891325E (pt) * 1996-03-29 2002-07-31 Searle & Co Derivados do acido fenilpropanoico para-substituido como antagonistas de integrina
CA2274594C (en) * 1996-12-16 2006-10-10 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
PE20000127A1 (es) * 1997-12-22 2000-03-14 Novartis Ag Derivado de bencenosulfonamida

Also Published As

Publication number Publication date
DE60001190T2 (de) 2003-10-09
ZA200001908B (en) 2000-10-31
CN1272493A (zh) 2000-11-08
US6596749B2 (en) 2003-07-22
BR0001602A (pt) 2001-08-21
CA2305940A1 (fr) 2000-10-15
CN1145616C (zh) 2004-04-14
US6245916B1 (en) 2001-06-12
DE60001190D1 (de) 2003-02-20
HUP0001562A2 (hu) 2001-04-28
ATE231133T1 (de) 2003-02-15
PL339690A1 (en) 2000-10-23
EA200000327A2 (ru) 2000-10-30
NO20001964D0 (no) 2000-04-14
EA003023B1 (ru) 2002-12-26
DK1044970T3 (da) 2003-04-22
HU0001562D0 (en) 2000-06-28
HUP0001562A3 (en) 2003-05-28
US20010018522A1 (en) 2001-08-30
EP1044970A1 (fr) 2000-10-18
KR20010020732A (ko) 2001-03-15
NZ504023A (en) 2000-10-27
FR2792314A1 (fr) 2000-10-20
FR2792314B1 (fr) 2001-06-01
EP1044970B1 (fr) 2003-01-15
JP2000309579A (ja) 2000-11-07
NO20001964L (no) 2000-10-16
SI1044970T1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
ECSP045278A (es) Compuestos de oxo-azabicíclicos
PA8582801A1 (es) Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa
MX9300786A (es) Compuestos hipolipidaemicos.
ES2159922T3 (es) Nuevos derivados de bencimidazol, de benzoxazol y de benzotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR027335A1 (es) Compuestos de piperidina-4-sulfonamida, proceso de preparacion de los mismos, y composiciones farmaceuticas que los contienen
AR021068A1 (es) Benzoilpiridazinas y procedimientos para elaborarlas; preparados farmaceuticos que las contienen y procedimiento para elaborarlos, y utilizacion de dichasbenzoilpiridazinas
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2153019T3 (es) Derivados de benzo-dioxano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CO5590934A2 (es) Procedimiento de preparacion de derivados de equinocandina
ES2135351B1 (es) Derivados de 5-aroilnaftaleno.
ES2133686T3 (es) Nuevos derivados de benzopirano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
UY24697A1 (es) Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa
ES2172376B1 (es) Nuevos derivados de isoquinoleinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR029468A1 (es) Derivados de aminoacidos n-mercaptoacilados, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ES8800164A1 (es) Un procedimiento para preparar derivados de imidazolidina
ES2172294T3 (es) Nuevos derivados del 1-indanol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2192263T3 (es) Derivados de benzo(c)quinolizina, su preparacion y empleo como inhibidores de 5-alfa-reductasas.
ES8304122A1 (es) "procedimiento para la preparacion de derivados triptaminicos sustituidos de tieniloxipropanolaminas, racemicos y opticamente activos".
ES2169716T3 (es) Nuevos derivados de 2,3-metano-aminoacidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2174582T3 (es) Nuevos derivados de 1,2-ditiolano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES8800952A1 (es) Un procedimiento para la preparacion de derivados de carbapenem.
AR030002A1 (es) Compuestos de benzotiadiazina un proceso para su preparacion y composiciones farmaceuticas que los contienen
DE3689080D1 (de) Berbanderivate und ihre herstellung und pharmazeutische zubereitung.
AR042886A1 (es) Derivados de diarilmetilen piperidina, su preparacion y uso de los mismos tanto en composiciones farmaceuticas como en la fabricacion de medicamentos.
PE20030345A1 (es) 3,5-dihidroxi-2,2-dimetil-valeroamidas protegidas para la sintesis de epotilonas y derivados y un procedimiento para su preparacion